title: Antitumor effects of new-type recombinant interleukin-2.
abstract: Two new human recombinant interleukin-2 (rIL-2), 125-Ser-rIL-2, and 125-Ala-rIL-2, were generated by protein engineering technique. Both of them maintained the proliferation of natural killer (NK) cells, CTLL-2 cells and their long-term propagations. The mutated new rIL-2 also enhanced the bioactivity of NK cells and the cytotoxicity of tumor-infiltrating lymphocytes (TIL) against the target tumor cells. The above results were all compared with that of the native rIL-2 and a similarity between them was found, which indicates that new type rIL-2 could be used for adoptive immunotherapy of malignant diseases.
authors.affiliation: Department of Immunology, Shanghai Medical University, China.
authors.forename: X S
authors.initials: XS
authors.lastname: Feng
authors.forename: X J
authors.initials: XJ
authors.lastname: Zheng
authors.forename: Q S
authors.initials: QS
authors.lastname: Si
authors.forename: Y L
authors.initials: YL
authors.lastname: Lin
authors.forename: Y
authors.initials: Y
authors.lastname: Chang
authors.forename: P F
authors.initials: PF
authors.lastname: Fan
authors.forename: J L
authors.initials: JL
authors.lastname: Yu
authors.forename: S R
authors.initials: SR
authors.lastname: Zhang
authors.forename: X Y
authors.initials: XY
authors.lastname: Liu
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000502:physiology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology*; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins